Pharmaceutics (Feb 2020)

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

  • Nuseibah AL Qtaish,
  • Idoia Gallego,
  • Ilia Villate-Beitia,
  • Myriam Sainz-Ramos,
  • Tania Belén López-Méndez,
  • Santiago Grijalvo,
  • Ramón Eritja,
  • Cristina Soto-Sánchez,
  • Gema Martínez-Navarrete,
  • Eduardo Fernández,
  • Gustavo Puras,
  • José Luis Pedraz

DOI
https://doi.org/10.3390/pharmaceutics12030198
Journal volume & issue
Vol. 12, no. 3
p. 198

Abstract

Read online

Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed.

Keywords